Shytoshi Kusama, the lead ambassador of the Shiba Inu SHIB/USD fraternity, said on Monday he was preparing to make the “biggest announcement” ever connected to the blockchain ecosystem.
What Happened: Kusama took to X to tease the significant event, stating, “After some rest, I will focus back on Shib. Bone, Leash, and Treat as we gear up for the biggest announcement I’ve ever given.”
The statement comes after the mysterious personality outlined a roadmap to help support the growth of SHY, a community-backed consumer token inspired by himself. Kusama added that the “robust” approach will allow the project to compete with Hasbro, a renowned toy and game company.
A consumer token offering, or CTO, is a fundraising mechanism in which an entity directly sells cryptocurrencies to customers, granting them access to specific products or services within the blockchain ecosystem.
Interestingly, the Solana SOL/USD -based token plunged 72% over the last 24 hours, according to Dex Screener. As of this writing, it has accumulated a market capitalization of $6 million.
See Also: Robert Kiyosaki Predicts Yet Another Stock Market Crash, Pitches Bitcoin Investments — Here’s What The ‘Rich Dad Poor Dad’ Author Said
Why It Matters: Kusama’s remarks come shortly after his transition from the Shiba Inu lead visionary to the lead ambassador role. He stated that the Shiba Inu project now requires more execution and communication rather than vision.
The community has been brimming with the launch of its latest token, Shiba Inu TREAT (TREAT), a utility meme coin that provides rewards, governance, and liquidity.
TREAT is the latest addition to Shiba Inu's token arsenal which includes SHIB, the popular dog-themed cryptocurrency, Doge Killer (LEASH), and Bone ShibaSwap BONE/USD.
Price Action: At the time of writing, SHIB was exchanging hands at $0.0000191, up 7.26% in the last 24 hours, according to data from Benzinga Pro. TREAT was up 24.39%, while BONE rose 5.13%.
Read Next:
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
Image via Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
